Understanding Multiple Primary Cancers
Determining How Estrogen Alterations and Cancer Treatment Impact 2nd Cancer Risk for Individuals with the KRAS-variant
Individuals who carry the KRAS-variant are at greater risk of developing breast, ovarian, and lung cancers. Recent studies also show women with this marker are up to eleven times as likely to develop a second, independent breast cancer. The overall goal of this study is to determine how to prevent multiple primary cancers in patients with the KRAS-variant.
We believe that management strategies applied during a first breast cancer diagnosis may change the risk of a second breast cancer for women with the KRAS-variant. Management strategies may include hormone therapies (e.g., tamoxifen, arimidex, etc.), surgery (e.g., preventive mastectomy), and chemotherapy.
In this study we will investigate two things, first, how common a family history of multiple primary cancers is for people with the KRAS-variant, and second, for women with breast cancer, which strategy for breast cancer management is safest for women with the KRAS-variant. (Note: a second, independent breast cancer is not the same as a recurrence of the first breast cancer.)
If you are interested in participating in this research study, please complete our eligibility survey:
Apply to Participate!
Once you submit your survey, here is what you can expect:
- A MiraKind researcher will review your survey information, and you will then be sent the protocol and a consent to review.
- You will be given the contact information for a MiraKind researcher to ask any questions you may have about the study, before you consent.
- Once your questions have been answered you will be able to electronically sign the consent, and you will be enrolled in the study and sent your DNA collection kit.
- You will receive a follow up study specific questionnaire, as well as information on how to obtain individual results through a physician of your choice if you are interested in doing so.
- If you are not eligible for any MiraKind studies that are currently open but would like to stay updated on forthcoming studies, please join our e-newsletter.
- Here are some additional resources about MiraKind and this study: